Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective To investigate the status of the basal forebrain cholinergic system in primary progressive aphasia (PPA) as justification for cholinergic therapy. Methods A cohort of 36 brains from PPA participants with the neuropathology of Alzheimer disease (PPA-AD, n = 14) or frontotemporal lobar degeneration (PPA-tau, n = 12; PPA-TDP, n = 10) were used for semiquantitative rating of degeneration and gliosis of basal forebrain cholinergic neurons (BFCN). A subpopulation of 5 PPA-AD and 7 control brains underwent detailed analysis of BFCN pathology and cortical cholinergic axonal loss employing immunohistochemical and histochemical methods and stereologic analysis. Results Semiquantitatively, 11 (∼80%) PPA-AD participants were rated as having moderate/severe BFCN loss and gliosis, whereas none of the PPA-tau and only 1 (10%) PPA-TDP participant received such a rating. Detailed analysis in the subpopulation of PPA-AD participants revealed substantial tangle formation, loss of BFCN, and degeneration of cortical cholinergic axons. Compared to controls, loss of p75 low affinity neurotrophin receptor-positive BFCN was detected in the PPA-AD participants (p < 0.01). Acetylcholinesterase-positive cholinergic axons in all cortical areas studied displayed loss in PPA-AD (p < 0.005–0.0001). The loss was more severe in the language-dominant left hemisphere and, within the left hemisphere, in language-affiliated cortical areas. Conclusions Our results demonstrate prominent depletion of BFCN and cortical cholinergic axons in PPA-AD when compared with normal control or other neuropathologic variants of PPA. The demonstration of cholinergic denervation with an anatomy that fits the clinical picture suggests that cholinergic treatment is justified in patients with PPA who have positive AD biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Self-citationThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Self-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“Although the cholinergic degeneration starts very early in the aging–MCI–dementia continuum of AD pathology, a major clinical trial failed to show efficacy of ChEI inMCI.(37) However, the patients entered into the trial had no biomarker confirmation of AD and undoubtedly comprised a highly heterogeneous group with res…”
BackgroundAlzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Mesulam, M.-M., Weintraub, S., Rogalski, E. J., Wieneke, C., Geula, C., & Bigio, E. H. (2014) · Brain · doi:10.1093/brain/awu024 · Cited by 334
Self-citationProgression of language decline and cortical atrophy in subtypes of primary progressive aphasia
Rogalski, E., Cobia, D., Harrison, T. M., Wieneke, C., Weintraub, S., & Mesulam, M.-M. (2011) · Neurology · doi:10.1212/wnl.0b013e31821ccd3c · Cited by 252 · cited 6×
“One study reported a “trend” toward clinical efficacy of galantamine in a small group of patients with PPA.46 However, the patients were not selected based on AD biomarker positivity.”
BackgroundInfluentialSelf-citationGalantamine in Frontotemporal Dementia and Primary Progressive Aphasia
Kertesz, A., Morlog, D., Light, M., Blair, M., Davidson, W., Jesso, S., & Brashear, R. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000113034 · Cited by 217 · cited 6×
“One study reported a “trend” toward clinical efficacy of galantamine in a small group of patients with PPA.46 However, the patients were not selected based on AD biomarker positivity.”
BackgroundInfluentialSystematic Regional Variations in the Loss of Cortical Cholinergic Fibers in Alzheimer's Disease
Geula, C., & Mesulam, M.-M. (1996) · Cerebral Cortex · doi:10.1093/cercor/6.2.165 · Cited by 202
Self-citation
Cited by
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
Self-citation
Metadata
- Authors
- Mesulam, M.-M., Lalehzari, N., Rahmani, F., Ohm, D., Shahidehpour, R., Kim, G., Gefen, T., Weintraub, S., Bigio, E., & Geula, C.
- Venue
- Neurology
- Published
- 2019-04-02
- Volume
- 92
- Issue
- 14
- Pages
- e1580-e1588
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2921747289
- Cited by
- 39
- References
- 9
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. https://app.cochat.ai/papers/10.1212/wnl.0000000000007247
- The paper
- Mesulam, M.-M., Lalehzari, N., Rahmani, F., Ohm, D., Shahidehpour, R., Kim, G., Gefen, T., Weintraub, S., Bigio, E., & Geula, C. (2019). Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. Neurology. https://doi.org/10.1212/wnl.0000000000007247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.